Skip to main content

ICBII announces approval of two US patents and filing of two divisional patent applications in Europe.

By December 18, 2018February 28th, 2019Press Releases

La Jolla, California, USA, Innovative California Biosciences International, Inc., (“ICBII”), announced on December 21, 2018 that the US Patent Office granted two of its patents, making the total approved number of patents five. The patents relate to the blood-brain barrier permeable peptide compositions. “We still have five pending office actions and more than a dozen new applications to file”, says Dr. Ram Bhatt, Founder of ICBII.  Dr. Bhatt went on saying that “The Company’s IP portfolio is becoming robust every day, which will aid in launching CNS products in the near future”.

ICBII also announced in December, 2018 that it was invited by Alzheimer’s Society International Congress to present its science at the February, 2019 Alzheimer’s Conference in San Francisco.

Furthermore, ICBII was pleased to announce its collaboration with Dr. David Vera,  Professor of Radiology at the University of California, San Diego (UCSD). Dr. Vera is a world renowned authority in the design and synthesis of targeted diagnostic agents capable of measuring receptor density and affinity. He has developed the first to be FDA approved Tc-99m-galactosyl-neoglycoalbumin, the first technetium-99m labeled receptor-binding radiopharmaceutical for commercial human-use. Dr. Bhatt says that collaboration with Dr. Vera will help ICBII develop radiolabeled SMART Molecules for imaging Alzheimer’s, Parkinson’s and MSA animals.